News: Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

224.80DKK
22 Aug 2014
Price Change (% chg)

kr.-0.70 (-0.31%)
Prev Close
kr.225.50
Open
kr.226.80
Day's High
kr.227.30
Day's Low
kr.221.50
Volume
117,601
Avg. Vol
179,752
52-wk High
kr.260.00
52-wk Low
kr.163.40

Search Stocks
Select another date:

Wed, Aug 13 2014

Genmab raises 2014 operating income guidance

COPENHAGEN, Aug 13 - Danish biotech company Genmab increased its 2014 operating income guidance to between 175 million and 250 million Danish crowns ($31-45 million) from a previous 140 million to 210 million crowns due to its expectations of higher revenues.

BRIEF-Genmab announces new phase III study of daratumumab

Aug 11 - Genmab A/S : * Announces new phase III study of daratumumab in front line multiple myeloma * Says study expected to start in the first half of 2015 Source text for Eikon:

BRIEF-Genmab expects royalty payment of around DKK 23 mln

COPENHAGEN, July 23 - Genmab A/S : * Says worldwide net sales of Arzerra (ofatumumab) in the second-quarter 2014 totaled GBP 12.8 million ($21.8 million) * Says expects royalty payment of approximately 23 million Danish crowns ($4.2 million) Source text for Eikon:

BRIEF-Genmab to start new phase III study of daratumumab

COPENHAGEN, July 18 - Genmab A/S : * Partner, Janssen Biotech, Inc. plans to start a new phase III study of

BRIEF-Genmab to receive 25 mln USD milestone payment from Janssen

COPENHAGEN, July 7 - Genmab A/S : * Reaches $25 million milestone in Daratumumab collaboration with Janssen * Milestone triggered by progress in the phase III study of Daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma * Milestone payment is included in Genmab's 2014 financial guidance published on May 1, 2014. Source text for Eikon:

BRIEF-Genmab and GSK gets EU approval for Arzerra in combination

COPENHAGEN, July 3 - Danish biotech company Genmab :

GSK, Genmab leukemia drug fails to meet main trial goal

June 27 - GlaxoSmithKline Plc and Genmab A/S said on Friday their cancer drug Arzerra failed to treat a type of leukemia more effectively than other drugs in a late-stage trial.

BRIEF-Genmab in research collaboration about technology platforms

COPENHAGEN, June 4 - Genmab A/S : * Announced a research collaboration with an undisclosed biotechnology company which would use and evaluate Genmab's proprietary antibody technologies, the DuoBody and HexaBody platforms * The financial terms of the agreement have not been disclosed and agreement will not have a material impact on Genmab's financial results and cash position * The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies t

BRIEF-Genmab receives positive opinion from EMA commitee on Arzerra

COPENHAGEN, May 23 - Danish biotech company Genmab A/S said on Friday: * GSK and Genmab has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Arzerra in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy. * Final decision from European commission expected in the coming months

Glaxo, Genmab say disappointed with study of lymphoma treatment

- GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval.

Select another date:
Search Stocks